ArticleWorld journal of microbiology & biotechnology2026
From gene to enzyme: Microbial engineering of bovine chymosin for efficient cheese coagulation.
Article in World journal of microbiology & biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chymosin, an aspartic protease, specifically cleaves the Phe105-Met106 bond in κ-casein to initiate milk coagulation, making it indispensable for cheese production. Owing to ethical, economic, and supply limitations associated with calf-derived rennet, recombinant production in microbial hosts has become a preferred alternative. This study integrated molecular docking and molecular dynamics (MD) simulations with experimental heterologous expression to enhance structural understanding and recombinant production efficiency. MD simulation (20 ns) supported structural stability (RMSD ~ 0.4-0.5 nm; Rg 2.4-2.5 nm), while docking with κ-casein yielded a stable complex (lowest binding energy - 943.9 kcal/mol), consistent with catalytic functionality. A codon-optimized prochymosin gene (PylB promoter, YwbN signal peptide) was expressed in Escherichia coli BL21-CodonPlus (pET28a), Bacillus subtilis KO7 (pHFS-chy/PylB), and Bacillus thuringiensis 4Q7 (pPFS-chy/cyt). E. coli achieved high-level expression (40.61 kDa; optimized at 1.0 mM IPTG, 37 °C, 12 h), producing 800 OD₂₈₀ units of inclusion bodies from 5 L culture. In contrast, B. subtilis exhibited delayed and weak intracellular expression (~ 40.6 kDa at 120 h), and B. thuringiensis showed transient expression at 24 h. Inclusion bodies were solubilized with 95.25% recovery, refolded, purified via anion-exchange chromatography (~ 14.8% recovery), and activated by acid treatment (pH 2 → pH 6). The activated enzyme demonstrated milk-clotting activity comparable to the native counterpart (66.6 MCU/mL; 6 min clotting time). Collectively, these findings establish E. coli as an efficient platform for recombinant chymosin production, while indicating that Bacillus systems require further optimization for enhanced secretion and yield.
Indexed as
Identifiers
42440191What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.